Arrhythmia Alliance News & Events
WORLD HEART RHYTHM WEEK 5-11 JUNE 2017 TAKE THE PULSE CHECK CHALLENGE – IT COULD SAVE YOUR LIFE
HIGH RISK AF PATIENTS DENIED ACCESS TO LIFE-SAVING TREATMENT
New patient survey results show 80% of AF patients say ‘YES’ to the freedom that INR self-monitoring gives them
The purpose of this survey was to help discover patient thoughts and opinions about INR self-monitoring versus clinic visits. Several trials have demonstrated that patient self-monitoring (PSM) by those on long term warfarin significantly improves time in therapeutic range (TTR) and leads to better management outcomes.
Arrhythmia Alliance Launches APPG-A
Arrhythmias are a critical health concern in the UK, but the necessary policy attention and resource focus is limited. There are many issues from a management and service provision perspective that need to be addressed for the benefit of patients and the NHS. A strong political voice is necessary to help raise these issues and help to effect positive change.
Combination of principal component analysis and optical-flow motion compensation for improved cardiac MR thermometry
The use of magnetic resonance (MR) thermometry for the monitoring of thermal ablation is rapidly expanding. However, this technique remains challenging for the monitoring of the treatment of cardiac arrhythmia by radiofrequency ablation due to the heart displacement with respiration and contraction. Recent studies have addressed this problem by compensating in-plane motion in real-time with optical-flow based tracking technique.
Arrhythmia Alliance Medical Director Named President Elect of British Heart Rhythm Society
Friday 21 October, Birmingham, UK: Arrhythmia Alliance is pleased to announce that its Medical Director, Professor Richard Schilling, St Bartholomew’s Hospital, London has been chosen as the next President of the British Heart Rhythm Society – the world’s first heart rhythm society established in 1976. This further reinforces the strong links between the UK’s leading Heart Rhythm Charity and the Cardiac Specialists professional organization, combining the voice of the patient with that of the physician.
Arrhythmia Alliance places 3000th Public Access Defibrillator on World Restart the Heart Day
“AEDs must be as commonplace as fire extinguishers and smoke alarms if we are to dramatically reduce the number of deaths from sudden cardiac arrest in the UK.”
New real-world analysis reports lower risk of major bleeding with dabigatran compared to rivaroxaban in stroke prevention
Ingelheim, Germany, 13.October 2016 – A large observational study by researchers from the U.S. FDA has found that dabigatran (150 mg twice daily) was associated with lower rates of intracranial haemorrhage and major extracranial bleeding, including major gastrointestinal bleeding than rivaroxaban (20 mg once daily) in patients with atrial fibrillation (AF). The study is the largest observational study to-date comparing the two drugs, and analysed data from over 118,000 AF patients. Based on the data published in JAMA Internal Medicine, the accompanying Editor’s Note written by Parks and Redberg suggests that physicians should “prescribe dabigatran over rivaroxaban for patients with atrial fibrillation.”
HEART RHYTHM CONGRESS DEBATES NEED FOR SCREENING OF UNKNOWN OR UNDIAGNOSED ATRIAL FIBRILLATION (AF)
Thursday 13 October, Heart Rhythm Congress, Birmingham, UK: Many of the world’s leading authorities on the management and treatment of atrial fibrillation (AF) met at the Heart Rhythm Congress to debate the latest evidence supporting the value of screening for people with unknown AF.